Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib.

Welslau M, Fasching PA, Semmler-Lins N, Mueller L, Belleville E, Rieger L, Uhrig S, Zahn MO, Lex B, Uleer C, Deuerling N, Hesse T, Langanke D, Häberle L, Tesch H

Open source

DOI
10.1016/j.breast.2025.104684
Published
2026 Feb
Container
Breast (Edinburgh, Scotland)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.breast.2025.104684,
  title = {Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib.},
  author = {Welslau M and Fasching PA and Semmler-Lins N and Mueller L and Belleville E and Rieger L and Uhrig S and Zahn MO and Lex B and Uleer C and Deuerling N and Hesse T and Langanke D and Häberle L and Tesch H},
  year = {2026},
  journal = {Breast (Edinburgh, Scotland)},
  doi = {10.1016/j.breast.2025.104684},
  url = {https://doi.org/10.1016/j.breast.2025.104684}
}

RIS

TY  - JOUR
TI  - Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib.
AU  - Welslau M
AU  - Fasching PA
AU  - Semmler-Lins N
AU  - Mueller L
AU  - Belleville E
AU  - Rieger L
AU  - Uhrig S
AU  - Zahn MO
AU  - Lex B
AU  - Uleer C
AU  - Deuerling N
AU  - Hesse T
AU  - Langanke D
AU  - Häberle L
AU  - Tesch H
PY  - 2026
JO  - Breast (Edinburgh, Scotland)
DO  - 10.1016/j.breast.2025.104684
UR  - https://doi.org/10.1016/j.breast.2025.104684
ER  - 

APA

M, W., PA, F., N, S., L, M., E, B., L, R., S, U., MO, Z., B, L., C, U., N, D., T, H., D, L., L, H., & H, T. (2026). Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib.. Breast (Edinburgh, Scotland). https://doi.org/10.1016/j.breast.2025.104684

Source records